OBJECTIVE: To conduct a longitudinal assessment of long-term cognitive outcome in patients with classical galactosemia. METHODS: Inclusion criteria were (1) previous assessment of IQ dating back >10 years with tests being comparable with the recent German tests HAWIK-III and HAWIE-R, (2) absence of illnesses other than galactosemia, (3) absence of foreign language problems, (4) enzymatic-metabolic proof of classical galactosemia, (5) compliance with dietary therapy, and (6) written informed consent. Twenty-three patients who fulfilled these criteria were found. They underwent the first IQ test at a mean age of 11 +/- 5 years and the second 13.6 to 15.5 years later at a mean age of 26 +/- 5 years. Results were corrected for the obsolescence of test norms (Flynn effect). RESULTS: Mean total IQ scores on the first and second tests were 78 +/- 14 and 73 +/- 15, respectively, and not significantly different. IQ scores in the average range were observed for 7 patients on the first test and for 5 patients on the second test. For 17 patients, the intraindividual IQ scores remained essentially unchanged. Five patients showed a decrease and 1 an increase of the IQ score over time. No consistent pattern of change was found with respect to performance or verbal IQ subscores or in achievements in the individual subtest. CONCLUSIONS: The results confirm the presence of reduced cognitive ability in classical galactosemia and present evidence for an absence of substantial galactosemia-induced aggravation of this impairment with increasing age, at least in patients from 4 to 40 years of age. It remains to be clarified whether a reduction of cognitive function in galactosemia may be initiated by an in utero toxicity of endogenously formed galactose and which role such a process may play in the development of intellectual deficiencies that are later maintained throughout life.
OBJECTIVE: To conduct a longitudinal assessment of long-term cognitive outcome in patients with classical galactosemia. METHODS: Inclusion criteria were (1) previous assessment of IQ dating back >10 years with tests being comparable with the recent German tests HAWIK-III and HAWIE-R, (2) absence of illnesses other than galactosemia, (3) absence of foreign language problems, (4) enzymatic-metabolic proof of classical galactosemia, (5) compliance with dietary therapy, and (6) written informed consent. Twenty-three patients who fulfilled these criteria were found. They underwent the first IQ test at a mean age of 11 +/- 5 years and the second 13.6 to 15.5 years later at a mean age of 26 +/- 5 years. Results were corrected for the obsolescence of test norms (Flynn effect). RESULTS: Mean total IQ scores on the first and second tests were 78 +/- 14 and 73 +/- 15, respectively, and not significantly different. IQ scores in the average range were observed for 7 patients on the first test and for 5 patients on the second test. For 17 patients, the intraindividual IQ scores remained essentially unchanged. Five patients showed a decrease and 1 an increase of the IQ score over time. No consistent pattern of change was found with respect to performance or verbal IQ subscores or in achievements in the individual subtest. CONCLUSIONS: The results confirm the presence of reduced cognitive ability in classical galactosemia and present evidence for an absence of substantial galactosemia-induced aggravation of this impairment with increasing age, at least in patients from 4 to 40 years of age. It remains to be clarified whether a reduction of cognitive function in galactosemia may be initiated by an in utero toxicity of endogenously formed galactose and which role such a process may play in the development of intellectual deficiencies that are later maintained throughout life.
Authors: Patricia P Jumbo-Lucioni; Kathryn Garber; John Kiel; Ivo Baric; Gerard T Berry; Annet Bosch; Alberto Burlina; Ana Chiesa; Maria Luz Couce Pico; Sylvia C Estrada; Howard Henderson; Nancy Leslie; Nicola Longo; Andrew A M Morris; Carlett Ramirez-Farias; Susanne Schweitzer-Krantz; Susanne Scheweitzer-Krantz; Catherine Lynn T Silao; Marcela Vela-Amieva; Susan Waisbren; Judith L Fridovich-Keil Journal: J Inherit Metab Dis Date: 2012-03-27 Impact factor: 4.982
Authors: Susan E Waisbren; Nancy L Potter; Catherine M Gordon; Robert C Green; Patricia Greenstein; Cynthia S Gubbels; Estela Rubio-Gozalbo; Donald Schomer; Corrine Welt; Vera Anastasoaie; Kali D'Anna; Jennifer Gentile; Chao-Yu Guo; Leah Hecht; Roberta Jackson; Bernadette M Jansma; Yijun Li; Va Lip; David T Miller; Michael Murray; Leslie Power; Nicolle Quinn; Frances Rohr; Yiping Shen; Amy Skinder-Meredith; Inge Timmers; Rachel Tunick; Ann Wessel; Bai-Lin Wu; Harvey Levy; Louis Elsas; Gerard T Berry Journal: J Inherit Metab Dis Date: 2011-07-21 Impact factor: 4.982
Authors: Lindsey Welling; Susan E Waisbren; Kevin M Antshel; Hugh-Owen Colhoun; Matthias Gautschi; Stephanie Grünewald; Rebecca Holman; Johanna H van der Lee; Eileen P Treacy; Annet M Bosch Journal: JIMD Rep Date: 2017-04-09
Authors: Emily L Ryan; Mary Ellen Lynch; Elles Taddeo; Tyler J Gleason; Michael P Epstein; Judith L Fridovich-Keil Journal: J Inherit Metab Dis Date: 2013-01-15 Impact factor: 4.982
Authors: Britt van Erven; Cynthia S Gubbels; Ron J van Golde; Gerard A Dunselman; Josien G Derhaag; Guido de Wert; Joep P Geraedts; Annet M Bosch; Eileen P Treacy; Corrine K Welt; Gerard T Berry; M Estela Rubio-Gozalbo Journal: Orphanet J Rare Dis Date: 2013-07-16 Impact factor: 4.123